BMS Taps into Circular RNA Potential with Shanghai Circode Bio Agreement
Shanghai Circode Bio has entered into a feasibility study cooperation agreement with US pharmaceutical giant...
AbbVie Partners with OSE Immunotherapeutics to Develop First-in-Class Immunotherapy OSE-230
AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE)...
AstraZeneca’s AZD0486 Receives NMPA Greenlight for Clinical Study in B-Cell Leukemia
AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, has received approval from the National Medical...
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to...
BMS’s Azacitidine, First Oral AML Therapy, Reaches GBA Patients via Special Policy
Bristol-Myers Squibb (BMS, NYSE: BMY), a leading US pharmaceutical company, has announced the clinical application...
Abbisko Therapeutics Reports Positive Phase I Results for ABSK061 in Solid Tumors at ESMO TAT 2024
Shanghai-based Abbisko Therapeutics Co., Ltd. (HKG: 2256) has revealed promising outcomes from a global, multi-center...
Cutia Therapeutic’s CU-20401 Shows Promising Safety and Efficacy in Phase I Abdominal Fat Reduction Study
Cutia Therapeutic (HKG: 2487), a China-based dermatology specialist, has announced the successful completion of a...
Shandong Buchang Pharmaceuticals Gets NMPA Greenlight for Phase I Study of BC001 in Solid Tumors
Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a Chinese pharmaceutical company, has announced that it...
Bayer’s BAY 2927088 Receives FDA Breakthrough Therapy Designation for HER2-Mutated NSCLC
The US Food and Drug Administration (FDA) has granted Germany-based Bayer AG (ETR: BAYN) breakthrough...
Haisco Pharmaceutical Gets NMPA Greenlight for HSK39775 Solid Tumor Drug Candidate
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it...
Gilead’s Biktarvy Receives FDA Approval for Expanded HIV Treatment Indication
Gilead (NASDAQ: GILD), a leading US pharmaceutical company, has been granted an indication extension approval...
Zai Lab Ltd Reports 31% YOY Growth in Product Revenues and Strategic Pipeline Expansion
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has released its financial...
Harbour BioMed Partners with Boostimmune to Develop Novel ADC Therapies
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the...
China’s NMPA Updates Rules for Administrative Penalty Discretions in Drug Supervision
The National Medical Products Administration (NMPA) has issued the “Rules for the Application of Administrative...
AstraZeneca’s Fasenra Matches Nucala in EGPA Trial and Shows Steroid Reduction Benefits
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has presented results from a Phase III trial...
BeiGene’s Tislelizumab Receives CHMP Recommendation for Three NSCLC Indications in Europe
BeiGene (NASDAQ: BGNE) has announced that the European Medicines Agency’s Committee for Medicinal Products for...
Shanghai Fosun Pharmaceutical Partners with Nanning City to Broaden Collaboration in Biopharma and Beyond
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196，HKG: 2196), a Chinese pharmaceutical heavyweight, has entered...
Everest Medicines Gets CDE Approval for Global Phase IIb Study of Zetomipzomib in Lupus Nephritis
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...
Alvotech Scores FDA Nod for Interchangeable High-Concentration Biosimilar to Humira
The US Food and Drug Administration (FDA) has granted approval to Iceland-based Alvotech’s (NASDAQ: ALVO)...
BeiGene Reports Record Revenues and Rapid Growth in Q4 and Full Year 2023 with Continued Expansion
BeiGene (NASDAQ: BGNE), a China-based biopharmaceutical company, has presented its financial results for the fourth...